Ironwood Pharmaceuticals 3Q 2026: Revenue $133.04M, EPS $0.36 — 10-Q Summary

Ironwood Pharmaceuticals’ third-quarter revenue and net income rose year over year, with revenue growth driven primarily by increased U.S. LINZESS prescription demand, partly offset by net price. Earnings also benefited from lower selling, general and administrative costs and no restructuring expen…